论文部分内容阅读
目的:探讨C60-AEDP对Walker-256乳腺癌肉瘤骨破坏的影响。方法:建立SD大鼠Walker-256乳腺癌肉瘤骨破坏模型,随机分组药物处理后处死,测量瘤质量、治疗前后SD大鼠的质量、血清钙、磷、碱性磷酸酶的变化、胫骨破坏的程度、左右胫骨的质量。结果:AEDP组和C60-AEDP组的血钙水平分别为(2.36±0.21)和(2.29±0.31)mmol/L,血AKP水平分别为25.54±4.32和20.50±2.50(金氏单位),差异有统计学意义,P<0.05;光镜和X片结果显示,无破坏大鼠数分别为12只和10,且C60-AEDP组的瘤体质量较其他组明显减轻,平均为(4.29±1.79)g,差异有统计学意义,P<0.05。结论:C60-AEDP有抗瘤和保护骨组织免遭肿瘤的破坏作用,但该药有使SD大鼠体质量减轻的趋势,需进一步开展药物安全性方面的评价。
Objective: To investigate the effect of C60-AEDP on the bone destruction of Walker-256 breast cancer sarcoma. Methods: The bone destruction model of Walker-256 breast cancer sarcoma was established. The rats were randomly divided into groups and sacrificed after treatment. The quality of tumor, the changes of serum calcium, phosphorus, alkaline phosphatase, Degree, about the quality of the tibia. Results: The serum calcium levels of AEDP group and C60-AEDP group were (2.36 ± 0.21) and (2.29 ± 0.31) mmol / L respectively, and the serum levels of AKP were 25.54 ± 4.32 and 20.50 ± 2.50 The results of light microscopy and X-ray showed that the number of non-destructive rats was 12 and 10 respectively, and the tumor mass of C60-AEDP group was significantly lower than that of other groups (average 4.29 ± 1.79) g, the difference was statistically significant, P <0.05. Conclusion: C60-AEDP has antitumor and protective effects against tumor destruction. However, C60-AEDP tends to reduce the body weight of SD rats. It is necessary to evaluate the safety of C60-AEDP.